Wellington Management Group LLP Gracell Biotechnologies Inc. Transaction History

Wellington Management Group LLP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.95 - $5.5 $1.46 Million - $4.13 Million	-750,092 Reduced 68.73%	341,327 $1.88 Million
Q1 2022 May 16, 2022	SELL	$1.83 - $5.52 $5.86 Million - $17.7 Million	-3,200,722 Reduced 74.57%	1,091,419 $2.54 Million
Q4 2021 Feb 11, 2022	SELL	$5.65 - $14.9 $3.77 Million - $9.95 Million	-668,016 Reduced 13.47%	4,292,141 $25.9 Million
Q3 2021 Nov 15, 2021	BUY	$9.91 - $14.84 $15.9 Million - $23.8 Million	1,604,942 Added 47.83%	4,960,157 $68.8 Million
Q2 2021 Aug 16, 2021	BUY	$9.75 - $18.42 $6.92 Million - $13.1 Million	709,693 Added 26.83%	3,355,215 $43.6 Million
Q1 2021 May 17, 2021	BUY	$14.7 - $30.57 $38.9 Million - $80.9 Million	2,645,522 New	2,645,522 $40.7 Million

75.1K

Ticker GRCL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,674,096
Description
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the tre...

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

Stay updated on Wellington Management Group LLP with notifications on news.